Abstract
BACKGROUND It may take months to years until drugs specifically designed to treat COVID-19 are available. Until then, it is crucial to identify whether existing medications could have a protective effect against severe disease. This is the objective of this large population study performed in Clalit Health Services (CHS), the largest healthcare provider in Israel.
METHODS CHS centrally manages electronic health records (EHRs) including medication purchases for over 4.5 million members. Two case-control matched cohorts were assembled to assess systematically which drugs affected the risk of COVID-19 hospitalization: in both cohorts, case patients were hospitalized for COVID-19; matched control patients were taken from the general population in the first cohort, and non-hospitalized SARS-CoV-2 positive patients in the second cohort. For each medication anatomical-therapeutic-chemical (ATC) class acquired during the last month before the index-date, we computed the odds ratio (OR) for hospitalization, 95% confidence interval (CI), and the p-value, using Fisher’s exact test. False discovery rate was used to adjust for multiple testing.
RESULTS Several drugs and pharmacy sold items were associated with significantly reduced odds for SARS-CoV-2 hospitalization, notably ubiquinone (OR=0.185, 95% CI [0.058,0.458], p<0.001), ezetimibe (OR=0.513, 95% CI [0.375,0.688], P<0.001), rosuvastatin (OR=0.746, 95% CI [0.645,0.858], p<0.001) and flecainide (OR=0.303, 95% CI [0.080,0.813], p<0.01). Additionally, acquisition of surgical masks, latex gloves and several ophthalmological products were associated with decreased risk for hospitalization.
CONCLUSION Ubiquinone, ezetimibe and rosuvastatin, all related to the cholesterol synthesis pathway were associated with reduced hospitalization risk. These findings suggest a promising protective effect which should be further investigated.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported in part by the Intramural Research Program of the National Institutes of Health, NCI.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the CHS Institutional Review Board (IRB) with a waiver of informed consent, approval number: COM-0046-20
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Manuscript revised, Table 3 corrected, Figure 2 added
Data Availability
This study is based on patients' clinical data and cannot be shared outside of Clalit Health Services
